Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507751
2.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263519
3.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826360
4.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166679
5.
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Oncol
; 18(3): 323-335, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28131786
6.
Patient subgroup identification for clinical drug development.
Stat Med
; 36(9): 1414-1428, 2017 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28147447
7.
Methodology for Good Machine Learning with Multi-Omics Data.
Clin Pharmacol Ther
; 115(4): 745-757, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965805
8.
Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.
J Clin Pharmacol
; 63(12): 1359-1370, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37464901
9.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231178125, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37275963
10.
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Clin Cancer Res
; 28(5): 851-859, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965945
11.
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Eur J Cancer
; 76: 36-44, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28282611
12.
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Lung Cancer
; 90(2): 296-301, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26424209
13.
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Cancer Chemother Pharmacol
; 69(4): 911-21, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22080168
14.
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Mol Imaging Biol
; 14(5): 617-24, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22167582
15.
Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].
Eur J Cancer
; 81: 242, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28606464
16.
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Clin Cancer Res
; 18(11): 3163-9, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496272
17.
Phenotypic fingerprinting of small molecule cell cycle kinase inhibitors for drug discovery.
Curr Chem Genomics
; 3: 13-21, 2009 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20161832